Smart Insulin Pump Cuts A1c by 0.8% in Type 2 Diabetes

What This Study Found

A clinical trial published in JAMA Network Open tested whether an automated insulin delivery (AID) system — a "smart" insulin pump — could help adults with type 2 diabetes manage their blood sugar more effectively.

Who Was Studied

The trial included 305 adults aged 18–75 with type 2 diabetes who were already using insulin. The group was diverse:

• 57% were women
• 24% were Black, 22% Hispanic or Latino, 50% White
• Most (73%) were using multiple daily injections before the study
• Many were also taking GLP-1 medications (like Ozempic) or SGLT-2 inhibitors (like Jardiance)

How the Study Worked

Participants first spent 2 weeks on their usual therapy, then switched to the Omnipod 5 automated insulin delivery system for 13 weeks. This device automatically adjusts insulin delivery based on continuous glucose monitor readings.

Key Results

• A1c dropped from an average of 8.2% down to 7.4% — a meaningful 0.8 percentage point improvement
• Time in healthy range (70–180 mg/dL) jumped from 45% to 66% of the day — that's roughly 5 more hours per day in a safe range
• Low blood sugar episodes did not increase — the system was as safe as standard therapy
• Only 1 severe hypoglycemia episode occurred; no cases of diabetic ketoacidosis
• Benefits were seen across all groups regardless of age, sex, race, insurance type, or other diabetes medications

Why This Matters for You

Automated insulin delivery systems have been widely used in type 1 diabetes, but evidence for type 2 diabetes has been limited. This study shows that the technology can work well for type 2 diabetes too — even alongside other common medications like GLP-1 agonists or SGLT-2 inhibitors.

Important Limitations

This was not a randomized controlled trial, meaning there was no comparison group on standard therapy throughout the full study. Longer-term studies are still needed.